LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

LLY

996.4

-0.46%↓

JNJ

243

-0.23%↓

ABBV

228.13

+0.39%↑

NVS

155.63

-3.52%↓

AZN

192.84

-1.3%↓

Kodu・Aktsiate loetelu・Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Avatud

4.96 -3.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.75

Max

5.09

Põhinäitajad
By Trading Economics
Sissetulek	23T 23T
Töötajad	8
EBITDA	481K -6.7M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+80.61% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	38M 338M
Eelmine avamishind	8.65
Eelmine sulgemishind	4.96

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.9 / 2.65 Toetus ja vastupanu

Aldeyra Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. dets 2025, 11:43 UTC

Suurimad hinnamuutused turgudel

Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

3. apr 2025, 22:40 UTC

Suurimad hinnamuutused turgudel

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

Võrdlus sarnastega

Hinnamuutus

Aldeyra Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

80.61% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD 80.61%

Kõrge 10 USD

Madal 9 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Aldeyra Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Aldeyra Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.9 / 2.65Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.